↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Abbott sheds a stable but low-growth **$8B** nutrition arm to refocus on high-margin devices, even as core divisions miss 2026 targets.
$8 billion
in annual revenue—into a standalone public company while lowering…
$16.4 billion
in 2023
18%
but limited top-line expansion
25%
and growth rates justify premium valuations
Abbott Laboratories announced it will separate its nutrition business—roughly $8 billion in annual revenue—into a standalone public company while lowering its 2026 sales growth forecast, a dual signal that margin pressure in diagnostics and established pharmaceuticals has forced structural rethinking. The nutrition unit, which includes the Similac infant formula line and adult brands like Ensure, will be spun to shareholders in a tax-free transaction expected to close by late 2025 or early 2026. Abbott did not specify the new entity's name or leadership.
The company simultaneously reduced its 2026 sales growth guidance to a mid-single-digit percentage, down from prior expectations of high-single digits. Management attributed the revision to softer-than-expected performance in its diabetes care and established pharmaceuticals segments, both of which face intensifying competition from generics and new continuous glucose monitoring entrants. Abbott's diagnostics division, which generated $16.4 billion in 2023, has seen slowing demand for COVID-19 testing products and pricing compression in core immunoassay panels. The nutrition business, by contrast, posted stable margins near 18% but limited top-line expansion, making it a logical candidate for separation.
The spin matters because it crystallizes a broader trend among large-cap healthcare conglomerates: shedding consumer-facing or low-growth divisions to sharpen focus on higher-margin medical technology and pharma. Johnson & Johnson completed a similar move with Kenvue in 2023, and GE HealthCare separated from General Electric in early 2023. Abbott's remaining business will center on medical devices—particularly cardiovascular stents, continuous glucose monitors, and electrophysiology tools—where operating margins exceed 25% and growth rates justify premium valuations. The nutrition unit, however, will inherit a mature market with entrenched incumbents like Nestlé and Danone, plus regulatory overhang from the 2022 Sturgis, Michigan, formula plant shutdown that triggered nationwide shortages. That plant has since reopened, but reputational damage lingers among pediatricians and hospital procurement committees.
Allocators should note that Abbott's stock traded down 4.2% in after-hours following the announcement, erasing roughly $6 billion in market capitalization. The sell-off suggests investors view the guidance cut as more material than the strategic value of the separation. The spin will likely create a nutrition company with an enterprise value near $12-14 billion, assuming a 1.5x revenue multiple in line with peers like Nestlé Health Science. Family offices and activists may circle the new entity for margin improvement plays, as the division's 18% EBITDA margin trails best-in-class nutraceutical comps by 300-400 basis points. Abbott itself will retain a debt-free balance sheet and approximately $4 billion in annual free cash flow, positioning it to pursue tuck-in acquisitions in electrophysiology or structural heart.
Operators should track three follow-on events: Abbott will file the Form 10 registration for the nutrition spinco within 90-120 days, revealing capital structure, management team, and standalone cost base. Second, watch for activist positioning in the new entity by Q3 2025, particularly from firms that specialize in consumer health turnarounds. Third, monitor Abbott's 2025 capital allocation—management has historically returned 50-60% of free cash flow via dividends and buybacks, but the guidance cut may shift that mix toward buybacks if the stock remains depressed. Any acquisition activity in the $2-3 billion range would signal confidence that the core portfolio can offset the lost nutrition revenue.
The nutrition business generated $8.2 billion in 2023 sales, or roughly 19% of Abbott's total revenue, but contributed only 16% of operating income. By 2027, the remaining Abbott will derive over 70% of revenue from devices with double-digit growth potential, a profile that commands 18-20x forward earnings multiples rather than the blended 15-16x the company trades at today.
Branded by POPS4 · proof in 60 seconds
For the principal
The spinco will be a magnet for activists targeting margin expansion; consider the remaining Abbott for device exposure at a discount.
For the operator
Track Form 10 filing in 90-120 days for spinco debt structure; remaining Abbott likely deploys $2-3B toward device tuck-ins by mid-2025.
For the house
Short-term volatility creates entry for Abbott core device thesis; avoid spinco unless activist catalyst emerges within six months of separation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.